141 related articles for article (PubMed ID: 20339369)
1. Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men.
Gross C; Blasey CM; Roe RL; Belanoff JK
Obesity (Silver Spring); 2010 Dec; 18(12):2295-300. PubMed ID: 20339369
[TBL] [Abstract][Full Text] [Related]
2. Mifepristone treatment of olanzapine-induced weight gain in healthy men.
Gross C; Blasey CM; Roe RL; Allen K; Block TS; Belanoff JK
Adv Ther; 2009 Oct; 26(10):959-69. PubMed ID: 19888560
[TBL] [Abstract][Full Text] [Related]
3. [Metabolic side effects of risperidone in early onset schizophrenia].
Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats.
Beebe KL; Block T; Debattista C; Blasey C; Belanoff JK
Behav Brain Res; 2006 Aug; 171(2):225-9. PubMed ID: 16782211
[TBL] [Abstract][Full Text] [Related]
5. Persistent effects of mifepristone (RU-486) on cortisol levels in bipolar disorder and schizophrenia.
Gallagher P; Watson S; Elizabeth Dye C; Young AH; Nicol Ferrier I
J Psychiatr Res; 2008 Oct; 42(12):1037-41. PubMed ID: 18255098
[TBL] [Abstract][Full Text] [Related]
6. Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment.
Maayan LA; Vakhrusheva J
Hum Psychopharmacol; 2010 Mar; 25(2):133-8. PubMed ID: 20196182
[TBL] [Abstract][Full Text] [Related]
7. Combined receptor antagonist stimulation of the hypothalamic-pituitary-adrenal axis test identifies impaired negative feedback sensitivity to cortisol in obese men.
Mattsson C; Reynolds RM; Simonyte K; Olsson T; Walker BR
J Clin Endocrinol Metab; 2009 Apr; 94(4):1347-52. PubMed ID: 19141586
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents.
Arman S; Sadramely MR; Nadi M; Koleini N
Saudi Med J; 2008 Aug; 29(8):1130-4. PubMed ID: 18690305
[TBL] [Abstract][Full Text] [Related]
9. Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia.
Mackin P; Gallagher P; Watson S; Young AH; Ferrier IN
Aust N Z J Psychiatry; 2007 Apr; 41(4):321-6. PubMed ID: 17464718
[TBL] [Abstract][Full Text] [Related]
10. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.
Popovic V; Doknic M; Maric N; Pekic S; Damjanovic A; Miljic D; Popovic S; Miljic N; Djurovic M; Jasovic-Gasic M; Dieguez C; Casanueva FF
Neuroendocrinology; 2007; 85(4):249-56. PubMed ID: 17570902
[TBL] [Abstract][Full Text] [Related]
11. Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia.
Gallagher P; Watson S; Smith MS; Ferrier IN; Young AH
Biol Psychiatry; 2005 Jan; 57(2):155-61. PubMed ID: 15652874
[TBL] [Abstract][Full Text] [Related]
12. Mifepristone as a therapeutic agent in psychiatry.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2013 Jun; 51(6):11-4. PubMed ID: 23814820
[TBL] [Abstract][Full Text] [Related]
13. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents.
Maayan L; Correll CU
J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):517-35. PubMed ID: 22166172
[TBL] [Abstract][Full Text] [Related]
14. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
15. LLY-2707, a novel nonsteroidal glucocorticoid antagonist that reduces atypical antipsychotic-associated weight gain in rats.
Sindelar DK; Carson MW; Morin M; Shaw J; Barr RJ; Need A; Alexander-Chacko J; Coghlan M; Gehlert DR
J Pharmacol Exp Ther; 2014 Jan; 348(1):192-201. PubMed ID: 24163440
[TBL] [Abstract][Full Text] [Related]
16. Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone.
Doknic M; Maric NP; Britvic D; Pekic S; Damjanovic A; Miljic D; Stojanovic M; Radojicic Z; Jasovic Gasic M; Popovic V
Neuroendocrinology; 2011; 94(3):246-54. PubMed ID: 21986470
[TBL] [Abstract][Full Text] [Related]
17. Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder.
Scahill L; Jeon S; Boorin SJ; McDougle CJ; Aman MG; Dziura J; McCracken JT; Caprio S; Arnold LE; Nicol G; Deng Y; Challa SA; Vitiello B
J Am Acad Child Adolesc Psychiatry; 2016 May; 55(5):415-23. PubMed ID: 27126856
[TBL] [Abstract][Full Text] [Related]
18. Clinical and biological effects of mifepristone treatment for psychotic depression.
Flores BH; Kenna H; Keller J; Solvason HB; Schatzberg AF
Neuropsychopharmacology; 2006 Mar; 31(3):628-36. PubMed ID: 16160710
[TBL] [Abstract][Full Text] [Related]
19. Selective glucocorticoid receptor (type II) antagonists prevent weight gain caused by olanzapine in rats.
Belanoff JK; Blasey CM; Clark RD; Roe RL
Eur J Pharmacol; 2011 Mar; 655(1-3):117-20. PubMed ID: 21269600
[TBL] [Abstract][Full Text] [Related]
20. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months.
Kelly DL; Conley RR; Love RC; Horn DS; Ushchak CM
J Child Adolesc Psychopharmacol; 1998; 8(3):151-9. PubMed ID: 9853689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
